MA32347B1 - Gelule pour la prévention de maladies cardiovasculaires - Google Patents

Gelule pour la prévention de maladies cardiovasculaires

Info

Publication number
MA32347B1
MA32347B1 MA33268A MA33268A MA32347B1 MA 32347 B1 MA32347 B1 MA 32347B1 MA 33268 A MA33268 A MA 33268A MA 33268 A MA33268 A MA 33268A MA 32347 B1 MA32347 B1 MA 32347B1
Authority
MA
Morocco
Prior art keywords
prevention
capsule
cardiovascular disease
coated
tablets
Prior art date
Application number
MA33268A
Other languages
Arabic (ar)
English (en)
Inventor
Marta Guerrero
Anna Orriols
Pablo Martín
Manuel Raga
Original Assignee
Ferrer Int
Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40010466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32347(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of MA32347B1 publication Critical patent/MA32347B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une capsule pour la prévention de maladies cardiovasculaires qui comprend des comprimés enrobés d'acide acétylsalicylique, des comprimés enrobés de simvastatine ou de pravastatine, et des comprimés enrobés de lisinopril, de ramipil ou de périndopril. Les capsules sont utilisées pour la prévention de maladies cardiovasculaires chez des populations à haut risque
MA33268A 2008-03-28 2010-10-19 Gelule pour la prévention de maladies cardiovasculaires MA32347B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153615 2008-03-28
PCT/EP2009/053545 WO2009118359A2 (fr) 2008-03-28 2009-03-25 Capsule pour la prévention de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
MA32347B1 true MA32347B1 (fr) 2011-06-01

Family

ID=40010466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33268A MA32347B1 (fr) 2008-03-28 2010-10-19 Gelule pour la prévention de maladies cardiovasculaires

Country Status (34)

Country Link
US (1) US8753680B2 (fr)
EP (1) EP2273985B1 (fr)
JP (1) JP2011515445A (fr)
KR (1) KR20110007602A (fr)
CN (1) CN101980701A (fr)
AR (1) AR071094A1 (fr)
AU (1) AU2009228832A1 (fr)
BR (1) BRPI0909254A2 (fr)
CA (1) CA2720800C (fr)
CL (1) CL2009000767A1 (fr)
CO (1) CO6311069A2 (fr)
CR (1) CR11736A (fr)
CY (1) CY1117556T1 (fr)
DK (1) DK2273985T3 (fr)
EC (1) ECSP10010562A (fr)
ES (1) ES2569553T3 (fr)
GT (1) GT201000275A (fr)
HN (1) HN2010001979A (fr)
HR (1) HRP20160416T1 (fr)
HU (1) HUE028919T2 (fr)
IL (1) IL208455A0 (fr)
IS (1) IS8932A (fr)
MA (1) MA32347B1 (fr)
MX (1) MX2010010479A (fr)
NI (1) NI201000159A (fr)
NZ (1) NZ588239A (fr)
PL (1) PL2273985T3 (fr)
RU (1) RU2477123C2 (fr)
SI (1) SI2273985T1 (fr)
SV (1) SV2010003684A (fr)
TW (1) TW200944251A (fr)
UA (1) UA99758C2 (fr)
UY (1) UY31741A (fr)
WO (1) WO2009118359A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
FR2967577B1 (fr) 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN103006612B (zh) * 2012-12-28 2014-07-02 石雷 一种赖诺普利迟释缓释片剂及其制备方法
EP2810644A1 (fr) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Formulation orale pour le traitement de maladies cardiovasculaires
WO2016139982A1 (fr) * 2015-03-05 2016-09-09 日本電気株式会社 Procédé de détermination de panne dans une installation sans fil et système sans fil d'entité mobile
BE1023011B1 (nl) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylzuur tablet met onmiddellijke afgifte
ES2695503B2 (es) 2017-06-30 2020-05-08 Pharmalink S L Formulaciones encapsuladas
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
PL4299063T3 (pl) 2022-06-30 2024-06-10 Ferrer Internacional, S.A. Kapsułki doustne zawierające tabletki atorwastatyny wykazujące odpowiedni profil rozpuszczania i biodostępność
CN115671077A (zh) * 2022-11-18 2023-02-03 乐普药业股份有限公司 一种预防心脑血管疾病的复方微丸胶囊及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
JP2544052B2 (ja) * 1991-12-18 1996-10-16 日本エランコ株式会社 硬質ゼラチンカプセルへの錠剤充填装置
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1272165B1 (fr) * 2000-02-10 2010-12-01 BPSI Holdings, Inc. Compositions acryliques d'enrobage enterique
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2004080488A2 (fr) 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires
AU2004261212B2 (en) * 2003-07-28 2011-01-27 Dr. Reddy's Laboratories Ltd. Treatment and prevention of cardiovascular events
EP1657265B1 (fr) * 2003-08-20 2012-10-17 Shionogi & Co., Ltd. Nouvelle composition pour revetements
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2009022821A2 (fr) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Préparation combinée contenant un inhibiteur de hmg-coa reductase et aspirine et son procédé d'élaboration

Also Published As

Publication number Publication date
MX2010010479A (es) 2011-02-22
AR071094A1 (es) 2010-05-26
RU2010144131A (ru) 2012-05-10
EP2273985A2 (fr) 2011-01-19
NZ588239A (en) 2011-09-30
HN2010001979A (es) 2013-07-01
WO2009118359A3 (fr) 2010-05-06
ES2569553T3 (es) 2016-05-11
DK2273985T3 (en) 2016-04-25
HUE028919T2 (en) 2017-01-30
SV2010003684A (es) 2011-03-31
CY1117556T1 (el) 2017-04-26
HRP20160416T1 (hr) 2016-06-17
PL2273985T3 (pl) 2016-08-31
CA2720800A1 (fr) 2009-10-01
CO6311069A2 (es) 2011-08-22
IS8932A (is) 2010-10-05
CR11736A (es) 2011-05-11
UY31741A (es) 2009-12-14
AU2009228832A1 (en) 2009-10-01
GT201000275A (es) 2015-09-30
UA99758C2 (ru) 2012-09-25
SI2273985T1 (sl) 2016-06-30
BRPI0909254A2 (pt) 2017-01-10
NI201000159A (es) 2011-08-02
WO2009118359A2 (fr) 2009-10-01
CL2009000767A1 (es) 2009-08-14
ECSP10010562A (es) 2011-04-29
US8753680B2 (en) 2014-06-17
CN101980701A (zh) 2011-02-23
RU2477123C2 (ru) 2013-03-10
IL208455A0 (en) 2010-12-30
EP2273985B1 (fr) 2016-02-17
JP2011515445A (ja) 2011-05-19
TW200944251A (en) 2009-11-01
CA2720800C (fr) 2013-07-30
KR20110007602A (ko) 2011-01-24
US20110086094A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
MA32347B1 (fr) Gelule pour la prévention de maladies cardiovasculaires
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
WO2006108582A3 (fr) Genes marqueurs humains et agents de diagnostic, de traitement et de prophylaxie des troubles cardio-vasculaires et de l'atherosclerose
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA33299B1 (fr) Nouvelle formulation de naproxène
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
MA32635B1 (fr) Produit medicamenteux et traitement associe
WO2008112840A3 (fr) Nouvelle composition et nouveaux procédés de traitement des maladies immunologiques
NO20076663L (no) Immunoglobuliner
MA54028B2 (fr) Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
BRPI0602206A (pt) forma polimórfica de dexcetoprofeno trometamol, sua preparação e composições que a contêm
ATE508737T1 (de) Clopidogrel-hydrogensulfat von polymorph 1 form enthaltende pharmazeutische zusammensetzung
TNSN08497A1 (fr) Composition nasale et buccale pour lutter contre le ronflement
WO2010047559A2 (fr) Formulations pharmaceutiques a liberation prolongee
EA200701932A1 (ru) Таблетка для профилактики и лечения заболеваний зубов и пародонта
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
UA87224C2 (ru) Применение 24-нор-урсодеоксихолевой кислоты для лечения холестатических заболеваний печени